Analysts Set Kodiak Sciences Inc. (NASDAQ:KOD) Target Price at $42.14
MarketBeat reports that eight brokerages covering Kodiak Sciences (NASDAQ:KOD) give an average “Moderate Buy” rating, with one sell, one hold, and six buy ratings. The average 1-year price target is $42.14. UBS raised its target to $80; HC Wainwright set $58; Chardan lifted to $61. KOD shares opened at $32.94 and last reported EPS of ($0.94) for May 7, slightly below consensus.
How this was made
The 30-second read
Why it matters
The article aggregates brokerages’ rating changes and updated 1-year price targets, which can influence short-term positioning but does not introduce new company-specific operational or regulatory information.
Market read
Consensus 1-year target is cited at ~$42.14 with several buy ratings, but the article is a recap of prior dated research notes rather than a new fundamental disclosure.
What to watch
The article also notes the stock’s wide 12-month range ($3.43–$47.84) and recent EPS miss (-$0.94 vs -$0.93), which can cap upside despite higher targets.
Background
Kodiak Sciences is a clinical-stage ophthalmic biopharma focused on anti-VEGF antibody biopolymer conjugates (lead: KSI-301).
Ticker impact
Article cites multiple brokerage rating/price-target changes for Kodiak Sciences, including UBS raising its target to $80 and HC Wainwright to $58.
Near-term bias modestly higher on upgrade/target headlines; follow-through depends on upcoming fundamental updates beyond this article.
The text provides specific target changes and consensus target ($42.14) but does not disclose new trial results, filings, or guidance—so impact is likely limited to positioning and sentiment rather than fundamentals.
Market effects
Reinforces bullish sell-side sentiment toward ophthalmic/anti-VEGF pipeline names, but without new data it’s more sentiment than sector re-rating.
Limited; primarily affects US small/mid-cap biotech sentiment.
Low; no cross-border regulatory or trial developments mentioned.
Counterpoint
Target increases may reflect model optimism rather than new evidence; without fresh trial/regulatory milestones, price may revert if expectations outrun fundamentals.
Key entities
- companyKodiak Sciences, Inc.
Clinical-stage biopharmaceutical company; subject of analyst target/rating updates in the article.
- brokerageUBS Group
Raised its Kodiak Sciences target price from $50 to $80 and reiterated a buy rating.
- brokerageHC Wainwright
Reissued a buy rating and increased its target to $58 from $38.
- brokerageChardan Capital
Upgraded from neutral to buy and lifted its target from $14 to $61.
